434 related articles for article (PubMed ID: 30778352)
1. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
2. Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis.
Su Q; Zhang XC; Zhang CG; Hou YL; Yao YX; Cao BW
J Immunol Res; 2018; 2018():1027323. PubMed ID: 29971244
[TBL] [Abstract][Full Text] [Related]
3. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I
Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347
[TBL] [Abstract][Full Text] [Related]
4. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
De Velasco G; Je Y; Bossé D; Awad MM; Ott PA; Moreira RB; Schutz F; Bellmunt J; Sonpavde GP; Hodi FS; Choueiri TK
Cancer Immunol Res; 2017 Apr; 5(4):312-318. PubMed ID: 28246107
[TBL] [Abstract][Full Text] [Related]
6. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
Tiu BC; Zubiri L; Iheke J; Pahalyants V; Theodosakis N; Ugwu-Dike P; Seo J; Tang K; Sise ME; Sullivan R; Naidoo J; Mooradian MJ; Semenov YR; Reynolds KL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705313
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions.
Hong B; Zheng J; Chen R; Zheng C; Du B; Ni R; Yang J
Drug Saf; 2023 Dec; 46(12):1313-1322. PubMed ID: 37934397
[TBL] [Abstract][Full Text] [Related]
8. Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis.
Zhang C; Wei F; Ma W; Zhang J
Front Immunol; 2024; 15():1255825. PubMed ID: 38318172
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis.
Huang S; Zheng G; Yang K
World J Surg Oncol; 2023 Nov; 21(1):349. PubMed ID: 37926852
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
González-Rodríguez E; Rodríguez-Abreu D;
Oncologist; 2016 Jul; 21(7):804-16. PubMed ID: 27306911
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer.
van Holstein Y; Kapiteijn E; Bastiaannet E; van den Bos F; Portielje J; de Glas NA
Drugs Aging; 2019 Oct; 36(10):927-938. PubMed ID: 31317421
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer].
Zhang S; Liu J; Cheng Y
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):623-628. PubMed ID: 28935016
[TBL] [Abstract][Full Text] [Related]
13. Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review.
Galle P; Finn RS; Mitchell CR; Ndirangu K; Ramji Z; Redhead GS; Pinato DJ
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38238030
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary adverse events following immune checkpoint inhibitors.
Spagnolo P; Chaudhuri N; Bernardinello N; Karampitsakos T; Sampsonas F; Tzouvelekis A
Curr Opin Pulm Med; 2022 Sep; 28(5):391-398. PubMed ID: 35838354
[TBL] [Abstract][Full Text] [Related]
15. Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Vardarli I; Tan S; Brandenburg T; Weidemann F; Görges R; Herrmann K; Führer D
J Clin Endocrinol Metab; 2024 Mar; 109(4):1132-1144. PubMed ID: 37967245
[TBL] [Abstract][Full Text] [Related]
16. Toxicities associated with checkpoint inhibitors-an overview.
Spiers L; Coupe N; Payne M
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment.
Kim YJ; Lee JS; Lee J; Lee SC; Kim TI; Byeon SH; Lee CS
Cancer Immunol Immunother; 2020 Dec; 69(12):2441-2452. PubMed ID: 32556494
[TBL] [Abstract][Full Text] [Related]
18. Effect of Sequence of Radiotherapy Combined With Immunotherapy on the Incidence of Pneumonitis in Patients With Lung Cancer: A Systematic Review and Network Meta-Analysis.
Mi S; Liang N; Zhang Y; Zhang Y; Wang F; Qiao L; Chen F; Hu P; Zhang J
Clin Lung Cancer; 2024 Jan; 25(1):18-28.e3. PubMed ID: 37612176
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Qiu J; Cheng Z; Jiang Z; Gan L; Zhang Z; Xie Z
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791528
[TBL] [Abstract][Full Text] [Related]
20. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
Vaddepally RK; Kharel P; Pandey R; Garje R; Chandra AB
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
